GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reissued by equities research analysts at Shore Capital in a report released on Thursday, ThisIsMoney.Co.Uk reports.
A number of other research analysts also recently issued reports on the stock. UBS Group reissued a “buy” rating and set a GBX 1,900 ($24.99) price objective on shares of GlaxoSmithKline in a research report on Monday, December 2nd. DZ Bank boosted their price objective on shares of GlaxoSmithKline from GBX 1,850 ($24.34) to GBX 2,000 ($26.31) and gave the company a “buy” rating in a research report on Thursday, October 31st. HSBC set a GBX 2,110 ($27.76) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research report on Wednesday, December 18th. Jefferies Financial Group boosted their price objective on shares of GlaxoSmithKline from GBX 1,850 ($24.34) to GBX 2,000 ($26.31) and gave the company a “buy” rating in a research report on Tuesday, December 17th. Finally, Liberum Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline in a research report on Friday, November 15th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of GBX 1,876.47 ($24.68).
Shares of GlaxoSmithKline stock opened at GBX 1,846 ($24.28) on Thursday. The company has a current ratio of 0.82, a quick ratio of 0.50 and a debt-to-equity ratio of 183.00. The company’s fifty day simple moving average is GBX 1,776.73 and its two-hundred day simple moving average is GBX 1,705.67. The company has a market cap of $92.11 billion and a P/E ratio of 20.22. GlaxoSmithKline has a 12-month low of GBX 1,429.80 ($18.81) and a 12-month high of GBX 1,851.15 ($24.35).
In other GlaxoSmithKline news, insider Vivienne Cox bought 308 shares of GlaxoSmithKline stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of GBX 1,725 ($22.69) per share, with a total value of £5,313 ($6,988.95). Insiders bought a total of 330 shares of company stock worth $569,837 over the last ninety days.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Story: Percentage Gainers
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.